Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra) in Subjects With Primary Immunodeficiency

Next Previous
X
Search
Trial Profile

An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra) in Subjects With Primary Immunodeficiency

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Acronyms HiLo
  • Sponsors CSL Behring

    • Most Recent Events

    • 21 Apr 2020 According to a CSL Behring media release, results from this trial were published in an online supplement to The Journal of Allergy and Clinical Immunology.
    • 21 Apr 2020 Results presented in the CSL Behring media release.
    • 16 Mar 2020 Results (N=16), of manual push flow rate cohort assessing safety of subcutaneous IgPro20 administration via manual push at high flow rates, published on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top